Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The purpose of the study is to find out if depemokimab works better than placebo in treating people with this lung disease who have a type of inflammation called Type 2 inflammation. The study will look at whether the medication can reduce the number of times symptoms suddenly get worse, which doctors call exacerbations. These are times when breathing problems become much worse and may need treatment with antibiotics or steroid pills, or sometimes even a visit to the emergency room or hospital.

During the study, people will receive treatment for up to 104 weeks, which is about two years. The doctors will check how often breathing problems get worse, how long it takes before problems get worse, and how the disease affects daily life and breathing symptoms. The study will compare results between people receiving depemokimab and those receiving placebo to see if the medication helps reduce flare-ups and improves quality of life for people with this lung condition.

The purpose of the study is to see if MET097 helps participants lose more weight than the placebo after about 64 weeks. Throughout the trial, participants will visit the clinic regularly for weight checks, safety assessments, and blood tests, including a measurement of HbA1c, a test that shows the average blood‑sugar level over the past two to three months. Additional evaluations will monitor changes in cholesterol, blood pressure, and overall health status, and the study will continue with follow‑up visits for up to roughly 84 weeks.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to determine if the combination of ceralasertib and durvalumab is more effective than docetaxel in treating patients with this type of lung cancer. Participants in the study will be randomly assigned to receive either the combination therapy or docetaxel. The study will monitor the overall survival of participants, which refers to the length of time patients live after starting the treatment. Other aspects being evaluated include how long the cancer stays under control, the quality of life reported by participants, and the safety and tolerability of the treatments.

The study will take place over a period of time, with participants receiving treatment for up to 24 months. During this time, participants will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for patients with advanced or metastatic non-small cell lung cancer.

The purpose of this study is to determine if NBI-1065845 is effective and safe compared to placebo when used as an additional treatment for people with moderate to severe depression. Participants in this study will continue taking their regular antidepressant medication while also receiving either the study drug or placebo.

The study will monitor changes in depression symptoms over an 8-week period. Participants will need to attend regular appointments for evaluations of their depression symptoms using standardized rating scales that measure the severity of depression and how it affects daily functioning.

Participants in the study will be randomly assigned to receive either the new medication, the placebo, or Deucravacitinib. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will take place over several weeks, during which participants will take the medication orally and attend regular check-ups to monitor their progress and any side effects.

The goal is to determine if JNJ-77242113 can improve the symptoms of plaque psoriasis more effectively than the placebo or Deucravacitinib. Participants will be monitored for changes in their skin condition and overall health. The study aims to provide valuable information that could lead to new treatment options for people living with moderate to severe plaque psoriasis.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

During the study, participants will receive treatment for up to 12 months. The researchers will measure several things to see if the treatment is helping, including changes in body weight and appetite over a 12-week period. Body weight will be tracked from the beginning of the study, and appetite will be measured using a questionnaire that asks specific questions about eating and food-related concerns. The study will also look at muscle mass using imaging scans such as CT or MRI, which are types of medical imaging that create detailed pictures of the inside of the body. Physical function will be tested through simple exercises like a chair stand test, and daily physical activity levels will be monitored.

Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. Participants will also complete questionnaires about their quality of life, how severe their symptoms are, and whether they notice any changes in their condition. Blood samples will be taken to measure the levels of the medication in the body. The study will track overall health outcomes and how the cancer responds to ongoing treatment during this time.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

During the study, participants will receive either Eloralintide or a placebo through subcutaneous use, which means the medication is injected into the fatty tissue just under the skin. The medication is provided in a pre-filled syringe for once-weekly administration. This is a randomized and double-blind study, meaning that neither the participants nor the researchers know beforehand which treatment is being administered. This method is used to ensure the results are as objective as possible.

Participants in this study will be assigned to receive either MET097 or a placebo. The study is designed to compare how much body weight changes over a specific period of time. During the course of the trial, individuals will receive their assigned treatment once every week. The process involves monitoring weight changes and other health factors over a long period, extending up to 84 weeks, to observe the impact of the medication on overall health.

During the study, some participants will receive the active medicine, while others will receive a placebo. The research involves monitoring how the medicine affects the body over a period of time to see if it can change the way the disease progresses. The course of the study includes regular check-ups to observe any changes in health or how the lungs are functioning.

Participants will be compared against two other options. One option is Trimbow, which contains the same three active ingredients. The other comparison involves using beclometasone dipropionate alone. Some individuals may also receive a placebo. The study uses a cross-over design, meaning that participants will receive different treatments at different times during the course of the study to see how each one affects their breathing.

One of the main ways the study looks at how well the medicine works is by measuring the forced expiratory volume in 1 second, which is a test that calculates how much air a person can exhale quickly to check lung function. The study tracks these changes over a period of time to see how the different inhaled medications affect breathing capacity and overall control of the condition.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

The purpose of the study is to see how well Tirzepatide works compared to Dulaglutide in reducing major cardiovascular events, such as heart attacks or strokes, in people with Type 2 Diabetes who are at high risk for heart problems. Participants in the study will receive either Tirzepatide or Dulaglutide, along with their usual diabetes care, to see which treatment is more effective in preventing these serious heart-related events.

The study will take place over a period of time, during which participants will receive regular injections of either Tirzepatide or Dulaglutide. The researchers will monitor the participants’ health to track any occurrences of heart-related events. The goal is to determine if Tirzepatide is not only as effective as Dulaglutide but also if it might be superior in preventing major cardiovascular events in people with Type 2 Diabetes.

The purpose of the study is to evaluate the long-term effectiveness and safety of Tirzepatide in adults who are starting treatment early in their Type 2 Diabetes journey. Participants will be monitored for changes in their blood sugar levels, specifically looking at Hemoglobin A1c (HbA1c), which is a common measure of blood sugar control. The study will last for about 104 weeks, during which participants will receive either Tirzepatide or the intensified conventional care.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. The goal is to determine if Tirzepatide can provide a similar or better outcome in managing Type 2 Diabetes compared to the traditional methods. This research aims to offer insights into new treatment options for individuals with this condition.

The purpose of the study is to find out if cagrilintide semaglutide is at least as good as tirzepatide at lowering blood sugar levels, and whether it might be better at helping people lose weight. The study will also look at other health measures such as blood pressure, waist size, cholesterol levels, and overall quality of life. Additionally, the study will check how safe these medications are and what side effects people may experience while taking them.

People taking part in this study will receive either cagrilintide semaglutide or tirzepatide for 60 weeks. During this time, they will continue taking their current diabetes medications. Throughout the study, participants will have regular visits where their blood sugar levels, body weight, blood pressure, and other health measurements will be checked. Blood tests will be done to measure a substance called HbA1c, which shows average blood sugar levels over the past few months, as well as cholesterol and other blood fats. Participants will also be asked to complete questionnaires about their physical health and quality of life. The study team will monitor for any side effects, including episodes of low blood sugar, which can happen when blood sugar drops too much.

The purpose of the study is to evaluate how well these new combinations of immune system treatments work compared to dostarlimab alone in people with this type of cancer that shows the PD-L1 marker. The main measure of success will be looking at how many people experience either complete disappearance of their tumors or significant shrinking of their tumors during treatment. Participants will be assigned randomly to receive one of the treatment combinations, and the study will follow them for up to 24 months to track how their cancer responds.

During the study, participants will receive their assigned treatment through infusions into a vein, and doctors will regularly check how the tumors are responding using imaging scans and physical examinations. Tissue samples from the tumor will be needed to confirm that the cancer meets the study requirements and to check for the PD-L1 marker. The study is designed as an open-label trial, which means both the participants and their doctors will know which treatment is being given. This is a platform study using a master protocol, which means it is set up in a way that allows testing of multiple treatment combinations at the same time.

Tirzepatide is given as an injection under the skin using a pre-filled pen once a week. The study will compare people taking tirzepatide to people taking placebo to see if there is a difference in major health events. These events include death from any cause, heart attack that is not fatal, stroke that is not fatal, procedures to restore blood flow to the heart, or problems related to heart failure. The study is looking at whether tirzepatide can help prevent these serious health problems in people who are overweight or have obesity and also have heart disease or risk factors for heart disease such as smoking, abnormal levels of fats in the blood, high blood pressure, or kidney disease.

People in the study will continue taking the treatment for a period of time while doctors monitor their health and track whether any of these major health events occur. The study will measure how long it takes until the first occurrence of any of these serious health problems happens in people taking tirzepatide compared to those taking placebo. The treatment period can last up to 324 weeks.

People taking part in this study will have schizophrenia with symptoms that have gotten worse and will either be in the hospital or need to be in the hospital because of their condition. Their symptoms must have started getting worse within the past two months. Before joining the study, they must have been treated with other antipsychotic medications that worked for them in the past year. During the study, participants will be randomly assigned to receive either the brexpiprazole medication or placebo, and neither they nor their doctors will know which one they are getting. The treatment will be given by mouth as tablets.

The study will measure how much the symptoms change from the beginning of the study to week six. Doctors will use a standard rating scale to measure the symptoms of schizophrenia throughout the study period. The medication will be given once a week, and the study will track how well it works and whether it is safe for people with acute schizophrenia.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

The trial investigates whether a medication called Orforglipron, taken as a tablet once daily by mouth, can help reduce the number of incontinence episodes experienced each week. Orforglipron belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a natural hormone in the body that helps regulate appetite and body weight. By potentially helping participants lose weight, this medication may also reduce pressure on the bladder and improve incontinence symptoms. Some participants will receive placebo instead of the active medication.

The study aims to determine if Orforglipron is more effective than placebo in decreasing the frequency of urinary leakage episodes. Participants will take one tablet daily throughout the treatment period, and their incontinence episodes will be monitored and recorded. This is a Phase 3 trial sponsored by Eli Lilly, designed to evaluate both the effectiveness and safety of the medication in this specific patient population.